Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Acer Medical's 3-Year RORE % for the quarter that ended in Dec. 2025 was -8.95%.
The industry rank for Acer Medical's 3-Year RORE % or its related term are showing as below:
ROCO:6857's 3-Year RORE % is ranked worse than 58.67% of 600
companies
in the Healthcare Providers & Services industry
Industry Median: 1.2
vs ROCO:6857: -8.95
Acer Medical (ROCO:6857) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Acer Medical 3-Year RORE % Related Terms
Acer Medical 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Acer Medical's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6857 vs VEEV, BTSG, HQY: 3-Year RORE % Comparison
For the Health Information Services subindustry, Acer Medical's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acer Medical 3-Year RORE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Acer Medical's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Acer Medical's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
Acer Medical (ROCO:6857) has a 3-Year RORE % of -8.95 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Acer Medical and its competitors. According to the industry distribution chart, Acer Medical ranks #352 out of 600 companies in the Healthcare Providers & Services industry, placing it in the top 58.7%.
Is Acer Medical's 3-Year RORE % too high?
Acer Medical's current 3-Year RORE % is -8.95. Based on the distribution chart, Acer Medical ranks #352 out of 600 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Acer Medical has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Acer Medical's 3-Year RORE % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Acer Medical ranks #352 out of 600 companies for 3-Year RORE %. This places Acer Medical in the lower half of its industry. The industry median 3-Year RORE % is 1.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
The median 3-Year RORE % among Healthcare Providers & Services companies is 1.20, based on 600 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Acer Medical and its competitors. For the Healthcare Providers & Services industry, the median 3-Year RORE % is 1.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acer Medical's current 3-Year RORE % is -8.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acer Medical stock overvalued right now?
Based on GuruFocus' analysis, Acer Medical (ROCO:6857) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$265.56, compared to a current price of NT$91.90 — trading 65.4% below its estimated fair value. The current 3-Year RORE % is -8.95. Acer Medical's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Acer Medical (ROCO:6857), the current 3-Year RORE % is -8.95 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acer Medical (ROCO:6857) Overvalued in 2026?
Based on GuruFocus' analysis, Acer Medical stock appears to be undervalued.
The current stock price of NT$91.90 is trading 65.4% below its estimated GF Value™ of NT$265.56.
GuruFocus considers Acer Medical to be Significantly Undervalued.
Key valuation signals for ROCO:6857:
3-Year RORE %: -8.95
GF Value™: NT$265.56 vs. price of NT$91.90 (65.4% below fair value)
No single metric tells the full story. See the ROCO:6857 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acer Medical Inc focuses on improving human health and well-being through artificial intelligence. It focuses on applying artificial intelligence and large data to the area of healthcare. Acer Medical is capable of designing, developing, commercializing, as well as implementing AI solutions in medical institutions.
51GF Score
Get the complete analysis for ROCO:6857
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6857 has been successfully added to your 
